Tags

Type your tag names separated by a space and hit enter

Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells.
Biomol Ther (Seoul). 2020 Jun 15 [Online ahead of print]BT

Abstract

Axl receptor tyrosine kinase has been implicated in cancer progression, invasion, and metastasis in various cancer types. Axl overexpression has been observed in many cancers, and selective inhibitors of Axl, including R428, may be promising therapeutic agents for several human cancers, such as breast, lung, and pancreatic cancers. Here, we examined the cell growth inhibition mediated by R428 and auranofin individually as well as in combination in the human breast cancer cell lines MCF-7 and MDAMB- 231 to identify new advanced combination treatments for human breast cancer. Our data showed that combination therapy with R428 and auranofin markedly inhibited cancer cell proliferation. Isobologram analyses of these cells indicated a clear synergism between R428 and auranofin with a combination index value of 0.73. The combination treatment promoted apoptosis as indicated by caspase 3 activation and poly (ADP-ribose) polymerase cleavage. Cancer cell migration was also significantly inhibited by this combination treatment. Moreover, we found that combination therapy significantly increased the expression level of Bax, a mitochondrial proapoptotic factor, but decreased that of the X-linked inhibitor of apoptosis protein. Furthermore, the suppression of cell viability and induction of Bax expression by the combination treatment were recovered by treatment with N-acetylcysteine. In conclusion, our data demonstrated that combined treatment with R428 and auranofin synergistically induced apoptosis in human breast cancer cells and may thus serve as a novel and valuable approach for cancer therapy.

Authors+Show Affiliations

Center for Metareceptome Research, College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.Center for Metareceptome Research, College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.Center for Metareceptome Research, College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.Center for Metareceptome Research, College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.Center for Metareceptome Research, College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.Center for Metareceptome Research, College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.Center for Metareceptome Research, College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32536618

Citation

Ryu, Yeon-Sang, et al. "Synergistic Induction of Apoptosis By the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells." Biomolecules & Therapeutics, 2020.
Ryu YS, Shin S, An HG, et al. Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells. Biomol Ther (Seoul). 2020.
Ryu, Y. S., Shin, S., An, H. G., Kwon, T. U., Baek, H. S., Kwon, Y. J., & Chun, Y. J. (2020). Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells. Biomolecules & Therapeutics. https://doi.org/10.4062/biomolther.2020.051
Ryu YS, et al. Synergistic Induction of Apoptosis By the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells. Biomol Ther (Seoul). 2020 Jun 15; PubMed PMID: 32536618.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells. AU - Ryu,Yeon-Sang, AU - Shin,Sangyun, AU - An,Hong-Gyu, AU - Kwon,Tae-Uk, AU - Baek,Hyoung-Seok, AU - Kwon,Yeo-Jung, AU - Chun,Young-Jin, Y1 - 2020/06/15/ PY - 2020/04/03/received PY - 2020/05/14/revised PY - 2020/06/01/accepted PY - 2020/6/16/entrez KW - Auranofin KW - Axl receptor tyrosine kinase KW - Bax KW - Synergism JF - Biomolecules & therapeutics JO - Biomol Ther (Seoul) N2 - Axl receptor tyrosine kinase has been implicated in cancer progression, invasion, and metastasis in various cancer types. Axl overexpression has been observed in many cancers, and selective inhibitors of Axl, including R428, may be promising therapeutic agents for several human cancers, such as breast, lung, and pancreatic cancers. Here, we examined the cell growth inhibition mediated by R428 and auranofin individually as well as in combination in the human breast cancer cell lines MCF-7 and MDAMB- 231 to identify new advanced combination treatments for human breast cancer. Our data showed that combination therapy with R428 and auranofin markedly inhibited cancer cell proliferation. Isobologram analyses of these cells indicated a clear synergism between R428 and auranofin with a combination index value of 0.73. The combination treatment promoted apoptosis as indicated by caspase 3 activation and poly (ADP-ribose) polymerase cleavage. Cancer cell migration was also significantly inhibited by this combination treatment. Moreover, we found that combination therapy significantly increased the expression level of Bax, a mitochondrial proapoptotic factor, but decreased that of the X-linked inhibitor of apoptosis protein. Furthermore, the suppression of cell viability and induction of Bax expression by the combination treatment were recovered by treatment with N-acetylcysteine. In conclusion, our data demonstrated that combined treatment with R428 and auranofin synergistically induced apoptosis in human breast cancer cells and may thus serve as a novel and valuable approach for cancer therapy. SN - 1976-9148 UR - https://www.unboundmedicine.com/medline/citation/32536618/Synergistic_Induction_of_Apoptosis_by_the_Combination_of_an_Axl_Inhibitor_and_Auranofin_in_Human_Breast_Cancer_Cells L2 - http://www.biomolther.org/journal/DOIx.php?id=10.4062/biomolther.2020.051 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.